FY2029 Earnings Forecast for MGRM Issued By Roth Capital

Monogram Orthopaedics, Inc. (NASDAQ:MGRM) – Stock analysts at Roth Capital cut their FY2029 EPS estimates for Monogram Orthopaedics in a report released on Wednesday, April 16th. Roth Capital analyst J. Wittes now forecasts that the company will post earnings per share of $0.35 for the year, down from their previous estimate of $0.41. The consensus estimate for Monogram Orthopaedics’ current full-year earnings is ($0.49) per share.

Separately, Roth Mkm increased their price objective on shares of Monogram Orthopaedics from $4.00 to $5.40 and gave the company a “buy” rating in a report on Tuesday, March 18th.

Monogram Orthopaedics Stock Up 3.1 %

NASDAQ:MGRM opened at $2.70 on Thursday. The business’s 50-day simple moving average is $2.61 and its two-hundred day simple moving average is $2.50. Monogram Orthopaedics has a 52 week low of $1.82 and a 52 week high of $4.21. The stock has a market cap of $95.28 million, a PE ratio of -5.74 and a beta of 0.77.

Monogram Orthopaedics (NASDAQ:MGRM) last issued its quarterly earnings results on Wednesday, March 12th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.03.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Commonwealth Equity Services LLC lifted its position in Monogram Orthopaedics by 21.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 41,628 shares of the company’s stock valued at $99,000 after purchasing an additional 7,366 shares during the last quarter. Wells Fargo & Company MN grew its position in Monogram Orthopaedics by 286.6% in the 4th quarter. Wells Fargo & Company MN now owns 11,597 shares of the company’s stock valued at $27,000 after acquiring an additional 8,597 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Monogram Orthopaedics in the fourth quarter worth about $25,000. Barclays PLC bought a new position in Monogram Orthopaedics in the 3rd quarter worth about $29,000. Finally, Orion Portfolio Solutions LLC purchased a new position in Monogram Orthopaedics during the 4th quarter worth $31,000. Institutional investors own 0.45% of the company’s stock.

Monogram Orthopaedics Company Profile

Monogram Orthopaedics, Inc focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures.